Novavax (NASDAQ:NVAX) had its price target boosted by HC Wainwright from $10.00 to $17.00 in a research report report published on Wednesday morning, Briefing.com Automated Import reports. They currently have a buy rating on the biopharmaceutical company’s stock.
NVAX has been the topic of several other reports. Chardan Capital reissued a neutral rating and set a $7.00 price target on shares of Novavax in a research report on Friday, May 10th. Cantor Fitzgerald restated a hold rating on shares of Novavax in a research report on Thursday, May 9th. Oppenheimer upped their price objective on shares of Novavax from $1.25 to $25.00 in a research report on Monday, May 13th. ValuEngine upgraded Novavax from a sell rating to a hold rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Novavax from a hold rating to a buy rating and set a $8.00 price objective on the stock in a report on Thursday, May 16th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company’s stock. Novavax has a consensus rating of Hold and a consensus target price of $40.70.
Shares of NVAX stock traded up $0.39 on Wednesday, reaching $6.43. The company had a trading volume of 85,763 shares, compared to its average volume of 473,472. The firm has a market capitalization of $96.17 million, a PE ratio of -0.63 and a beta of 2.21. The stock’s 50-day simple moving average is $4.76. Novavax has a 12 month low of $4.01 and a 12 month high of $51.60.
Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.61) by ($0.08). The company had revenue of $3.36 million for the quarter, compared to analyst estimates of $3.53 million. During the same quarter last year, the firm earned ($2.40) earnings per share. As a group, sell-side analysts expect that Novavax will post -5.81 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the stock. Edmond DE Rothschild Holding S.A. increased its position in shares of Novavax by 86.7% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 1,537,130 shares of the biopharmaceutical company’s stock worth $847,000 after purchasing an additional 713,752 shares during the last quarter. Creative Planning raised its position in Novavax by 161.7% during the first quarter. Creative Planning now owns 513,324 shares of the biopharmaceutical company’s stock worth $283,000 after acquiring an additional 317,204 shares in the last quarter. SG Americas Securities LLC raised its position in Novavax by 3,799.2% during the first quarter. SG Americas Securities LLC now owns 435,107 shares of the biopharmaceutical company’s stock worth $240,000 after acquiring an additional 423,948 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Novavax by 21.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 123,100 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 22,000 shares during the last quarter. Finally, Ontario Teachers Pension Plan Board acquired a new stake in Novavax in the second quarter valued at $510,000.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Featured Article: Street Name
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.